Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Mycenax Finishes Phase II Trial of Biosimilar Drug

publication date: Oct 28, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Mycenax Biotech of Taiwan, a protein drug development company, reported TuNEX its biosimilar version of etanercept, a rheumatoid arthritis and psoriasis treatment, successfully completed a Phase I trial in South Korea and a Phase I/II trial in Taiwan. Etanercept is a TNF inhibitor marketed as Enbrel by Amgen (NSDQ: AMGN) and Wyeth (NYSE: WYE) and in Japan by Takeda Pharma. More details...

Stock Symbol: (GreTai: 4726)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners